Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ribera

Showing results (431-440 of 473) with videos related to

Pageof 48
Sort By:
Haematologica|June 22, 2001
Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIALJ J Ortega, J M Ribera, A Oriol, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Blood|November 11, 1999
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA groupM A Sanz, G Martín, C Rayón, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
Blood|August 18, 2005
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMAJoan Bladé, Laura Rosiñol, Ana Sureda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapyPau Montesinos, José D González, José González, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|September 8, 2020
The situation of infection in the elderly in Spain: a multidisciplinary opinion documentE Bouza, F J Brenes, J Díez Domingo, et al.
British Journal of Haematology|December 22, 2017
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow TransplantationAlicia Rovó, Austin Kulasekararaj, Michael Medinger, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Pageof 48

Showing results (431-440 of 473) with videos related to

Sort By:
Pageof 48
Haematologica|June 22, 2001
Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIALJ J Ortega, J M Ribera, A Oriol, et al.
Haematologica|June 13, 2015
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trialRamón García-Sanz, Albert Oriol, María J Moreno, et al.
Blood|November 11, 1999
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA groupM A Sanz, G Martín, C Rayón, et al.
Blood Cancer Journal|September 24, 2016
Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaN Gökbuget, M Kelsh, V Chia, et al.
Blood|August 18, 2005
High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMAJoan Bladé, Laura Rosiñol, Ana Sureda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapyPau Montesinos, José D González, José González, et al.
Leukemia|October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosisN C Gutiérrez, M V Castellanos, M L Martín, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|September 8, 2020
The situation of infection in the elderly in Spain: a multidisciplinary opinion documentE Bouza, F J Brenes, J Díez Domingo, et al.
British Journal of Haematology|December 22, 2017
Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow TransplantationAlicia Rovó, Austin Kulasekararaj, Michael Medinger, et al.
Leukemia Research|June 15, 2010
Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment sizeJ Nomdedeu, E Bussaglia, N Villamor, et al.
Pageof 48